Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2012 Results
Date:11/8/2012

$7,571, purchase accounting inventory fair value step-up of $3,146 and share-based compensation expense of $468.(g)

Revenue related to upfront and milestone payments.(h)

Share-based compensation expense of $6,986 and transaction and integration costs of $5,974. JAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED STATEMENTS OF DISCONTINUED OPERATIONS(In thousands)(Unaudited)Three Months Ended September 30, 2012Nine Months Ended September 30, 2012Product sales, net

$
8,086$
9,277Loss from discontinued operations

$
(386)$
(6,908) JAZZ PHARMACEUTICALS PLC  RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2012 FINANCIAL GUIDANCE  (In millions, except per share amounts)  GAAP income from continuing operations 

$140 - 151 Intangible asset amortization 

63 Share-based compensation expense 

23-24 Purchase accounting inventory fair value step-up 

17 - 18 Transaction, integration and restructuring costs 

22 - 24 Change in fair value of contingent consideration 

2 Other non-cash expense 

3 Income tax adjustments 

5-6 Adjusted net income 

$280 - 286 GAAP income from continuing operations per diluted share 

$2.34 - $2.49 Adjusted net income per diluted share 

$4.65 - $4.75 Shares used in computing per diluted share amounts 

60
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
2. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
4. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
5. Genoa Pharmaceuticals announces $1.2M Financing
6. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
7. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
8. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
9. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 On the afternoon ... parent company of CPI International, Inc. (CPI), plans to ... July 3, 2015 with the Securities and Exchange Commission ... for the quarter.  At 11 a.m. (EDT) on Wednesday, ... call in conjunction with this release that will be ...
(Date:7/28/2015)... -- Research and Markets ( ... "Craniomaxillofacial Implants Market - Global Industry Analysis, ... 2022" report to their offering. ... the current and future prospects of the global ... the global market due to increasing facial deformities ...
(Date:7/28/2015)... 28, 2015 At the 2015 ... Association recognized 15 winners in the categories of ... across multiple vertical markets. ContextMedia:Health proudly took ... for its success with its first-to-market Patient ... ContextMedia:Health, the leading provider of digital solutions ...
Breaking Medicine Technology:CPI International To Announce Third Quarter 2015 Financial Results 2Global Craniomaxillofacial Implants (Plate and Screw Fixator Systems, Bone Graft Substitutes, Distraction Systems, and TMJ Replacement Devices) Market Analysis 2014-2022 2ContextMedia:Health Receives Top Award at the ICX Association Excellence Awards 2
... SPRING, Md., Oct. 24, 2011 The U.S. ... generic versions of Zyprexa (olanzapine tablets) and Zyprexa ... and bipolar disorder. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... and disabling brain disorder. About 1 percent of ...
... BRANFORD, Conn., Oct. 24, 2011 Clarient, a ... signed a definitive agreement to provide pharma services ... pharma clients.  By implementing HistoRx,s AQUA technology in ... their complementary capabilities to serve pharma companies, growing ...
Cached Medicine Technology:FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 2FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 3Clarient Joins the HistoRx® Clinical Trials Network: First Commercial Lab to Provide Aqua® Technology for Clinical Trials 2
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Aziz Ahmad recently gave a talk on ... noon to 1 p.m. Tuesday, June 23, at the Gulf Coast Regional Medical Center ... is board-certified in colorectal surgery and has more than 35 years of experience in ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser ... skin to a smooth state, and reduces the appearance of fine lines and wrinkles. ... FDA-approved injectable gel to instantly add volume to your cheek area to correct age-related ...
(Date:7/28/2015)... ... ... to WFTV on July 15th heroin overdose rates have increased by 270 ... statistic Orlando suffers at least one death weekly as a direct result of a ... officials are struggling to keep apace with its distribution. Officers rely on inside information ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... targeted biologics and biologic-device combination products for the treatment of bone disorders and ... U.S. Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone". ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Women fear developing ... reason is that cancer, heart attack, and stroke are treatable, but there is little ... can do is to take part in a clinical trial, reports the July 2015 ...
Breaking Medicine News(10 mins):Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3
... Cardiovascular disease (CVD) death rates are declining, but CVD ... the United States, and risk factor control remains a ... from the American Heart Associations Heart Disease and Stroke ... available in the Dec. 17 online issue of Circulation: ...
... on an enzyme that is critical to the process ... target of antibacterial and anticancer drugs. Researchers with the ... Lab) and the University of California (UC) at Berkeley ... DNA-bound Type II topoisomerase (topo II) that is responsible ...
... for Dealing With Elderly Holiday Blues Offered by One of the ... ... of the country,s senior,healthcare experts from the world-renowned Los Angeles Jewish ... group,particularly vulnerable to the blues at this time of year -- ...
... CAMPAIGN "KICK ONE, PICK ONE" ENCOURAGING ... AND SPEND TIME TOGETHER, NEW YORK, Dec. 20 ... Nite announces the launch of "Kick One, Pick One",(KOPO), the ... fit and spend more time together. Bowing Jan. 1, KOPO ...
... children , , THURSDAY, Dec. 20 (HealthDay News) -- Holiday toys ... are threatening to cause more worry than joy. , Millions ... months by toy companies, many because they were decorated with ... Barbie, and Thomas the Tank Engine, among others. , The ...
... were given Nobel Direct dental implants, the risk of the ... at the Sahlgrenska Academy in Sweden shows that eight per ... was launched in 2004 by Nobel Biocare AB. The implants ... directly into the jawbone without having to first lift up ...
Cached Medicine News:Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 2Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 3Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 4Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 5Health News:First look at an enzyme target for antibacterial and cancer drugs 2Health News:First look at an enzyme target for antibacterial and cancer drugs 3Health News:First look at an enzyme target for antibacterial and cancer drugs 4Health News:It's Not Just About the Children 2Health News:It's Not Just About the Children 3Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 2Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 3Health News:Make Safe Toys Your Holiday Priority 2Health News:Make Safe Toys Your Holiday Priority 3Health News:Gloomy forecast for Nobel Direct after 3 years 2
... The ndigo OPTIMA Laser System is designed ... ablation using a near infrared laser source. ... the laser delivers a controlled level of ... to a temperature range where tissue necrosis ...
... a device intended for highly accurate measurements ... single most important metric for the diagnosis ... discovered in a large, randomized, five-year National ... mid-2002, the patients central cornea thickness (CCT) ...
Rapid Test Kit...
... Information System) is an open architecture system ... platform designed to communicate and manage patient ... be expanded in various ways, as NAVIS ... but also to fundus cameras and ophthalmic ...
Medicine Products: